ZYTIGA® (abiraterone acetate): BTG INTERNATIONAL LIMITED et al v. MSN PHARMACEUTICALS INC
The EKOS Control Unit 4.0 was specifically designed to support a new standard of PE treatment – allowing physicians to use one control unit to treat both pulmonary arteries. The color touchscreen allows physicians to easily monitor and independently manage two EKOS devices simultaneously, simplifying bilateral PE treatment. With new functionality and workflow-based intelligence, the EKOS Control Unit 4.0 is designed to support a medical team’s ability to perform at a high level – from cath lab to transport to intensive care unit.
A U.S. unit of British drug company BTG Plc pleaded guilty on Monday to improperly marketing its embolic device LC Bead, and will pay about $36 million to resolve its criminal and civil liability, the U.S. Department of Justice said.